BeiGene to go solo with cancer drug after Novartis deal termination

BeiGene and Swiss drugmaker Novartis have terminated a 2021 deal to jointly develop the Hong Kong-listed company's cancer drug, the companies said on Tuesday, marking the second such discontinuation in just over two months.